Onconetix Announces Material Agreement and Officer Changes

Ticker: ONCO · Form: 8-K · Filed: 2025-02-28T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, management-change, corporate-governance

TL;DR

Onconetix inked a big deal & shuffled execs on 2/24/25.

AI Summary

Onconetix, Inc. announced on February 24, 2025, the entry into a material definitive agreement and changes in its board and officer composition. The company also filed information regarding shareholder nominations and financial exhibits. This filing follows a name change from Blue Water Biotech, Inc. on April 24, 2023.

Why It Matters

This 8-K filing indicates significant corporate actions, including a new material agreement and changes in leadership, which could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — The filing details material agreements and changes in officers/directors, which can introduce uncertainty or signal strategic shifts.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Onconetix, Inc.?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.

What specific changes occurred regarding directors or officers on February 24, 2025?

The filing reports on the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements for certain officers, but the specific individuals and details are not in the provided text.

What is the significance of the shareholder nominations mentioned in the filing?

The filing includes information regarding shareholder nominations pursuant to Exchange Act Rule 14a-11, suggesting potential proxy contest or governance-related activities.

When did Onconetix, Inc. change its name from Blue Water Biotech, Inc.?

Onconetix, Inc. changed its name from Blue Water Biotech, Inc. on April 24, 2023.

What is the Standard Industrial Classification (SIC) code for Onconetix, Inc.?

The SIC code for Onconetix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001213900-25-018867.txt : 20250228 0001213900-25-018867.hdr.sgml : 20250228 20250228172952 ACCESSION NUMBER: 0001213900-25-018867 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250224 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250228 DATE AS OF CHANGE: 20250228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Onconetix, Inc. CENTRAL INDEX KEY: 0001782107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41294 FILM NUMBER: 25692431 BUSINESS ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 BUSINESS PHONE: 513-620-4101 MAIL ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Biotech, Inc. DATE OF NAME CHANGE: 20230424 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Vaccines Inc. DATE OF NAME CHANGE: 20190710 8-K 1 ea0232572-8k_onconetix.htm CURRENT REPORT false 0001782107 0001782107 2025-02-24 2025-02-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 24, 2025   Onconetix, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-41294   83-2262816 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   201 E. Fifth Street , Suite 1900 Cincinnati , Ohio   45202 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 513 ) 620-4101     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered Common Stock, par value $0.00001 per share   ONCO   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01. Entry Into a Material Definitive Agreement   The information set forth in Item 5.02 below regarding the Consulting Agree

View on Read The Filing